Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus. - Wikidata - awgldk - TriplyDB

Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus.

Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus.

http://www.wikidata.org/entity/Q33832148

about

Oncolytic viruses as therapeutic cancer vaccines Thunder and lightning: immunotherapy and oncolytic viruses collide Oncolytic viruses as immunotherapy: progress and remaining challenges Cancer immunotherapy: the beginning of the end of cancer?Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma.VSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signaling.The profile of tumor antigens which can be targeted by immunotherapy depends upon the tumor's anatomical site.Vesicular stomatitis virus oncolytic treatment interferes with tumor-associated dendritic cell functions and abrogates tumor antigen presentation.Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus.Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus.Treating tumors with a vaccinia virus expressing IFNβ illustrates the complex relationships between oncolytic ability and immunogenicity.Complex Dynamics of Virus Spread from Low Infection Multiplicities: Implications for the Spread of Oncolytic Viruses.Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer.The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated mice Murine Tumor Models for Oncolytic Rhabdo-Virotherapy.NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors.Vesicular stomatitis virus as a treatment for colorectal cancer Oncolytic vesicular stomatitis virus in an immunocompetent model of MUC1-positive or MUC1-null pancreatic ductal adenocarcinoma.Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity.Recent advances in oncolytic virus design.Oncolytic vaccines.Evolution of oncolytic viruses: novel strategies for cancer treatment.Oncolytic virus-mediated reversal of impaired tumor antigen presentation.Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer.Arming oncolytic viruses to leverage antitumor immunity.Intratumoral immunotherapy for melanoma.Targeting Melanoma with Cancer-Killing Viruses.Oncolytic Immunotherapy for Treatment of Cancer.Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma.Expressing human interleukin-15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of anti-tumor immunity.Dynamics of melanoma tumor therapy with vesicular stomatitis virus: explaining the variability in outcomes using mathematical modeling.Evaluation of vesicular stomatitis virus mutant as an oncolytic agent against prostate cancer.Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide Oncolytic Virotherapy and the Tumor Microenvironment.Vanadium: A Panacea for Resistance to Oncolytic Immunotherapy?Oncolytic Adenoviruses in Cancer Treatment.Oncotargeting by Vesicular Stomatitis Virus (VSV): Advances in Cancer Therapy.Oncolytic Vesicular Stomatitis Virus as a Viro-Immunotherapy: Defeating Cancer with a "Hammer" and "Anvil".

P2860

Q21245758-E553BAE3-88A7-4D96-AD86-7B2E3B83E97C Q24597894-5AE2BCDA-F71F-4FE7-8BF6-15CBBD37E695 Q26745942-CDB38BAC-4784-4C62-83A2-9590A26EDB0E Q26752277-B8265595-A0D1-492D-8B0A-97E81915BF39 Q27021839-1228EC8C-361C-4E6C-A947-8E7EF8B15280 Q34198856-2E867A07-309F-41AB-B728-99031087512A Q34473352-C7F96E86-2A06-4F6A-94EF-7061660779FB Q35212733-82CA923C-12AF-41DA-8B41-6007F641D432 Q35531563-995FE2C4-9951-4CA8-920B-25BA6EA25213 Q35575688-F1D8FB81-7619-40E0-8BFF-B62E59AC264F Q35596563-9E8E2D8F-66FC-4956-B307-1E0A86ACB988 Q35876239-25E631B3-18E0-4A5D-B3E4-AF8CC34C39BF Q36255281-DFB546B9-7E30-4557-85D9-1FF4E60BF09D Q36582819-6014B349-C3C0-400C-8FD0-86C440C8690E Q36664213-827128B7-A377-42BF-83C8-A12C3E7BC4A9 Q36673729-F6A8528E-B8EB-48BB-81C8-9511CA886919 Q36751597-E3C363F9-7C40-4FBE-A3A8-120504D53176 Q36890816-F2CA9A7D-8094-41A5-AF8B-D949D708EC45 Q36928614-5DCFB582-0DF7-467A-8445-B70FC1F8257A Q37123143-76430FFE-481C-4E36-A5EF-E9BC9DB82D6D Q37651860-1D71F41D-946C-4E0B-B52A-352591628DAD Q37865172-C31EBDE3-F0A0-4F35-9DC4-63294C6580BF Q38152474-DF0DDB7C-C930-4B24-A9F2-D4AB22BCAE19 Q38159802-BCD6ECB6-14A1-4B7F-BE5C-A4DC674B0070 Q38208315-A295356E-6DDA-49EC-BDB3-0783C7EC2EF2 Q38223419-449343E1-91B9-4476-B453-BBB08BDD756B Q38470166-0DA56C53-E2FA-4EE5-8AEC-B9BF194B33E8 Q38518518-EC50AAA5-D6A3-448C-A88D-0C87792CD53E Q38676416-2DF88802-F268-4533-9FC1-6531C0F6DC79 Q38848223-23CCA78E-2063-4721-A327-0C862D49AE72 Q39413447-78314A06-CE27-4CF0-988A-C6495EEBA9F4 Q39430229-1D0A9895-071E-47B5-9240-ACFC77FFA1BC Q39473679-ABE519F8-7074-4082-8EEF-6F8F99ECAF8E Q41379521-ED000082-A359-4A07-AC2C-B4E342D4B727 Q42157100-CC57DF25-7FBD-489A-A9A3-82B78DE77A8A Q47560690-E9586F9B-6898-4FBD-8132-35030D754865 Q49715030-6284262A-77CC-440D-9D54-2E74F734428D Q51849210-C6462DAB-6208-465C-AD7C-9EB0897D4B51 Q52688581-ECE5E2C3-B84F-45C9-ABAC-450289E16A6F Q54378300-22E7E7A0-682E-47D3-8E12-A4D2B34C66A1

P2860

Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus.

http://www.wikidata.org/entity/Q33832148

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

name

Interference of CD40L-mediated ...... ic vesicular stomatitis virus.

@ast

Interference of CD40L-mediated ...... ic vesicular stomatitis virus.

@en

Interference of CD40L-mediated ...... ic vesicular stomatitis virus.

@en-gb

type

label

Interference of CD40L-mediated ...... ic vesicular stomatitis virus.

@ast

Interference of CD40L-mediated ...... ic vesicular stomatitis virus.

@en

Interference of CD40L-mediated ...... ic vesicular stomatitis virus.

@en-gb

prefLabel

Interference of CD40L-mediated ...... ic vesicular stomatitis virus.

@ast

Interference of CD40L-mediated ...... ic vesicular stomatitis virus.

@en

Interference of CD40L-mediated ...... ic vesicular stomatitis virus.

@en-gb

P1433

Q33832148-D2F557ED-4692-4CC9-B50F-DFB2664B642C

P1476

Q33832148-4BE80D7E-9758-48BE-97DD-AE2FA5D90D47

P2093

Q33832148-5C700AE7-64E5-4443-B1AB-EFC8B1F5B730

Q33832148-7394E364-863B-4101-A696-B6675B4E62DF

Q33832148-828D7238-7F84-46A8-ADEE-1DF809A0DD02

Q33832148-96919C73-2347-403E-AEA4-95E22444CDF2

Q33832148-AACDFAAC-A185-48D7-963E-D958A40F255E

Q33832148-D3087BAA-301A-4989-A3F1-61FA29785A32

Q33832148-E11494E1-39E6-4181-A6BE-AE1530758E4A

Q33832148-EC2B95BB-00CC-4E7C-B7AF-514A2A3D5180

P2860

Q33832148-04C65148-937B-41F6-A97B-317D6126B804

Q33832148-0C04A222-BAAA-4315-8223-A443BF26EA4F

Q33832148-11F52E44-1A5F-4505-9057-796378E9E43A

Q33832148-1DBD2950-6108-4D9B-A0BC-AD455BD15B53

Q33832148-21E1C95E-4600-472E-8EB9-64F67571D62B

Q33832148-2203B9CC-CCFB-4C1D-B481-6F3EFCB844DF

Q33832148-23291643-CFD6-4814-AE91-C2AF6F236A30

Q33832148-23F892E4-79D8-456C-B119-7C7D7F491592

Q33832148-2AACF6BF-8EF1-45F0-8C68-D3D2EC6BF0BC

Q33832148-365401D2-E44B-4192-B6C9-E630F8432D1E

P304

Q33832148-C7FE70DA-BB0A-4C7F-84ED-60CC9D620D3E

P31

Q33832148-2E923E6D-6E99-4C10-AD9F-04A5A50E06EF

P356

Q33832148-9667964B-B7CC-43A6-BF31-13C800BFA5CF

P433

Q33832148-486469FC-E9AD-4E79-9668-D044CDAD3EFE

P478

Q33832148-A8D9A063-CA7A-4938-9A81-38F0FEBAF8B1

P50

Q33832148-1A753005-CD96-4BDF-995D-FC4BEC88254E

Q33832148-D31584AB-23A7-4610-AC91-8CDF7EC32CF6

P577

Q33832148-1B4DA4EB-8C51-49ED-A79F-388BF8EE19DE

P5875

Q33832148-BA13974B-BF11-4788-ADB4-694627D26214

P698

Q33832148-F93FE3F7-4F44-4658-8BB4-4446E1018A10

P921

Q33832148-146E09D6-4369-44B4-A8C6-2C9CC75DAAD9

Q33832148-CCDC223B-9FEF-4E67-BC8A-0BE8FFA3EE71

P932

Q33832148-1CE930EE-A36F-49E1-9267-ECF365F3481D

P356

P1433

Human Gene Therapy

P1476

Interference of CD40L-mediated ...... tic vesicular stomatitis virus

@en

P2093

Alan Melcher

http://www.w3.org/2001/XMLSchema#string

Glen N Barber

http://www.w3.org/2001/XMLSchema#string

Jill Thompson

http://www.w3.org/2001/XMLSchema#string

Phonphimon Wongthida

http://www.w3.org/2001/XMLSchema#string

Richard G Vile

http://www.w3.org/2001/XMLSchema#string

Rosa Maria Diaz

http://www.w3.org/2001/XMLSchema#string

Timothy Kottke

http://www.w3.org/2001/XMLSchema#string

Uma Thanarajasingam

http://www.w3.org/2001/XMLSchema#string

P2860

CD40-CD40 ligand

The CD40 antigen and its ligand

Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor

The murine double-stranded RNA-dependent protein kinase PKR is required for resistance to vesicular stomatitis virus.

The oncolytic effect of recombinant vesicular stomatitis virus is enhanced by expression of the fusion cytosine deaminase/uracil phosphoribosyltransferase suicide gene.

Recombinant vesicular stomatitis viruses from DNA.

Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease.

Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice.

VSV-tumor selective replication and protein translation.

Radiation-mediated up-regulation of gene expression from replication-defective adenoviral vectors: implications for sodium iodide symporter gene therapy.

P304

439-450

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1089/HUM.2009.143

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

Feorillo Galivo

P577

2010-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38097926

http://www.w3.org/2001/XMLSchema#string

P698

19922169

http://www.w3.org/2001/XMLSchema#string

P921

oncolytic virus

P932

2865217

http://www.w3.org/2001/XMLSchema#string